<DOC>
	<DOCNO>NCT00154804</DOCNO>
	<brief_summary>CCRT twice weekly paclitaxel cisplatin patient locally advanced esophageal cancer .</brief_summary>
	<brief_title>CCRT With Twice Weekly Paclitaxel Cisplatin Followed Surgery Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>The purpose study find clinical pathological response rate pre-operative concurrent chemoradiotherapy ( CCRT ) twice weekly paclitaxel cisplatin patient locally advanced esophageal cancer .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Pathologically proven SCC adenocarcinoma esophagus . 2 . Locally advanced esophageal cancer , define T3 and/or N1 disease . ( AJCC 1998 ) 3 . M1a disease define ( AJCC 1998 ) , include celiac lymph node lower thoracic esophageal cancer cervical lymph node involvement upper thoracic esophageal cancer . 4 . Age ≧ 18 y 5 . KPS ≧ 60 % 6 . Hemogram : WBC ≧ 4000/mm3 ANC ≧ 2000 /mm3 Platelet ≧ 100,000/mm3 . Biochemistry : GOT/GPT ≦ 3.5 time , Cr ≦ 1.5 mg/dl Bilirubin ≦ 2.0 mg/dl . 1 . Invasion surround organ ( T4 disease ) . 2 . Distant metastasis , except M1a disease . 3 . Patients refuse operation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>Concurrent Chemoradiotherapy</keyword>
	<keyword>Esophageal Cancer</keyword>
</DOC>